A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis

Completed · Phase 1/Phase 2

Conditions studied: Myelofibrosis

In brief

The purpose of this study is to evaluate the long-term effects of orally administered SAR302503 (TG101348) in patients with myelofibrosis who have completed the MF-TG101348-001 study.

Key facts

Study ID

NCT00724334

Run by

Bristol-Myers Squibb

People needed

42

Starts

2008-07-01

Expected to finish

2014-05-01

Last updated by the study team

2025-03-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Completion of MF-TG101348-001 study
• Diagnosis of myelofibrosis
• At least 18 years of age

You may not qualify if…

• Any acute or chronic medical abnormality that may increase the risk associated with study participation

Where it is running

• Investigational Site Number 840103 — La Jolla, California, United States
• Investigational Site Number 840102 — Stanford, California, United States
• Investigational Site Number 840105 — Boston, Massachusetts, United States
• Investigational Site Number 840106 — Ann Arbor, Michigan, United States
• Investigational Site Number 840104 — Rochester, Minnesota, United States
• Investigational Site Number 840101 — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.